Sana Biotechnology Spokesperson, At Morgan Stanley Healthcare Conference, Said Expects To File An IND Filing For SC291 Product Candidate In Autoimmune Diseases In Q4 2023; Expects Clinical Data From Evaluation Of SC291 In Autoimmune Diseases In 2024
Portfolio Pulse from Charles Gross
A spokesperson for Sana Biotechnology announced at the Morgan Stanley Healthcare Conference that the company expects to file an IND filing for its SC291 product candidate in autoimmune diseases in Q4 2023. They also expect clinical data from the evaluation of SC291 in autoimmune diseases in 2024.
September 13, 2023 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sana Biotechnology's announcement of its IND filing for SC291 in Q4 2023 and expected clinical data in 2024 may generate investor interest and potentially impact the company's stock price.
The announcement of the IND filing and expected clinical data for Sana Biotechnology's SC291 product candidate could generate investor interest in the company. This could potentially lead to an increase in the company's stock price in the short term, especially if the market perceives the product candidate as promising.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100